Tempus AI reported total contract value of $1.1 billion for 2025 by securing over 70 data and analytics agreements with leading pharmaceutical companies, up from 45 deals in the prior year. The company posted its first positive adjusted EBITDA in the third quarter of 2025, driven by accelerated adoption of its AI-enabled precision medicine platform among oncology and rare disease researchers. Revenue retention improved to 115% in Q3, reflecting expansion of existing customer engagements, while monthly recurring revenue grew 40% year-over-year. These figures underscore Tempus’s growing role as a strategic partner for drug developers seeking to leverage its multimodal data assets and analytical tools to optimize clinical trial design and biomarker discovery.

Tempus introduced Paige Predict, a digital pathology suite that analyzes hematoxylin and eosin whole-slide images to predict the presence of 123 clinically actionable biomarkers across 16 cancer types, including non-small cell lung, breast and colorectal cancers. Built on a foundation model trained on a combined Tempus-Paige cohort of over 200,000 de-identified patient records, the solution delivers automated probability scores within the standard clinical report. Early validation studies demonstrated sensitivity and specificity above 85% for key biomarkers such as PD-L1 and EGFR mutations. By informing the sequence of confirmatory molecular tests when tissue is limited, Paige Predict aims to reduce turnaround times by an average of two weeks and minimize repeat biopsies, potentially improving patient outcomes and streamlining pathology workflows.